Literature DB >> 15148857

Blood phenylalanine control in adolescents with phenylketonuria.

John H Walter1, Fiona J White.   

Abstract

In order to determine the degree of compliance with dietary treatment in adolescents with phenylketonuria (PKU) we have analysed blood phenylalanine (phe) results in 75 patients (42 male) aged between 10 and 20 years. We compared these results with the upper limit for blood phe and the blood sampling frequency as recommended by the United Kingdom's National Society for Phenylketonuria (NSPKU(UK)). The blood phe increased with age from a mean (1SD) of 0.51 mmol/l (0.19) at 10 years to 0.98 mmol/l (0.30) by 20 years. A mean of 17% (24) of samples were above the recommended range at 10 years, but this had increased to a mean of 75% (33) by 20 yrs. The frequency of blood sampling fell from a mean of 83% (32) of that recommended to under 51% (37) by 20 years. Control was not significantly better in females compared with males. We conclude that although compliance with treatment in PKU is acceptable for most patients at 10 years this is not the case by late adolescents and early adulthood.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15148857     DOI: 10.1515/ijamh.2004.16.1.41

Source DB:  PubMed          Journal:  Int J Adolesc Med Health        ISSN: 0334-0139


  31 in total

1.  Behavioural factors related to metabolic control in patients with phenylketonuria.

Authors:  M R Crone; F J van Spronsen; K Oudshoorn; J Bekhof; G van Rijn; P H Verkerk
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  Differential effects of low-phenylalanine protein sources on brain neurotransmitters and behavior in C57Bl/6-Pah(enu2) mice.

Authors:  Emily A Sawin; Sangita G Murali; Denise M Ney
Journal:  Mol Genet Metab       Date:  2014-02-08       Impact factor: 4.797

3.  'Ready to drink' protein substitute is easier is for people with phenylketonuria.

Authors:  A MacDonald; M Lilburn; P Davies; S Evans; A Daly; S K Hall; C Hendriksz; A Chakrapani; P Lee
Journal:  J Inherit Metab Dis       Date:  2006-05-30       Impact factor: 4.982

Review 4.  Erythrocyte-mediated delivery of recombinant enzymes.

Authors:  Vincenzo Leuzzi; Luigia Rossi; Claudia Gabucci; Francesca Nardecchia; Mauro Magnani
Journal:  J Inherit Metab Dis       Date:  2016-03-30       Impact factor: 4.982

5.  Demographic and Psychosocial Influences on Treatment Adherence for Children and Adolescents with PKU: A Systematic Review.

Authors:  Emma Medford; Dougal Julian Hare; Anja Wittkowski
Journal:  JIMD Rep       Date:  2017-08-25

6.  A novel compound-primed multiplex ARMS-PCR (CPMAP) for simultaneous detection of common PAH gene mutations.

Authors:  Maryam Shaykholeslam Esfahani; Ehsan Shaykholeslam Esfahani; Sadeq Vallian
Journal:  Metab Brain Dis       Date:  2018-04-03       Impact factor: 3.584

Review 7.  Oxidative stress in phenylketonuria: future directions.

Authors:  Júlio César Rocha; Maria João Martins
Journal:  J Inherit Metab Dis       Date:  2011-11-25       Impact factor: 4.982

Review 8.  Nutritional management of PKU with glycomacropeptide from cheese whey.

Authors:  D M Ney; S T Gleason; S C van Calcar; E L MacLeod; K L Nelson; M R Etzel; G M Rice; J A Wolff
Journal:  J Inherit Metab Dis       Date:  2008-10-29       Impact factor: 4.982

9.  High dose sapropterin dihydrochloride therapy improves monoamine neurotransmitter turnover in murine phenylketonuria (PKU).

Authors:  Shelley R Winn; Tanja Scherer; Beat Thöny; Cary O Harding
Journal:  Mol Genet Metab       Date:  2015-11-26       Impact factor: 4.797

10.  White matter integrity and executive abilities in individuals with phenylketonuria.

Authors:  Jo Ann V Antenor-Dorsey; Tamara Hershey; Jerrel Rutlin; Joshua S Shimony; Robert C McKinstry; Dorothy K Grange; Shawn E Christ; Desirée A White
Journal:  Mol Genet Metab       Date:  2013-04-06       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.